MRK Merck & Co Inc

  1. Stocks
  2. Healthcare
  3. NYSE: MRK

Price (delayed)

$130.72

Market cap

$331.07B

P/E Ratio

933.71

Dividend/share

$3

EPS

$0.14

Enterprise value

$359.28B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the ...

Highlights
The gross profit has grown by 5% year-on-year
MRK's gross margin is up by 3.7% year-on-year
The EPS has plunged by 98% YoY and by 92% from the previous quarter
The net income has dropped by 97% year-on-year and by 92% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.merck.com/
Peers: PFE JNJ LLY BMY

Key stats

What are the main financial stats of MRK
Market
Shares outstanding
2.53B
Market cap
$331.07B
Enterprise value
$359.28B
Valuations
Price to earnings (P/E)
933.71
Price to book (P/B)
8.81
Price to sales (P/S)
5.52
EV/EBIT
118.85
EV/EBITDA
52.11
EV/Sales
5.98
Earnings
Revenue
$60.12B
EBIT
$3.02B
EBITDA
$6.9B
Free cash flow
$9.14B
Per share
EPS
$0.14
Free cash flow per share
$3.6
Book value per share
$14.83
Revenue per share
$23.7
TBVPS
$26.59
Balance sheet
Total assets
$106.68B
Total liabilities
$69.04B
Debt
$35.06B
Equity
$37.58B
Working capital
$6.47B
Liquidity
Debt to equity
0.93
Current ratio
1.25
Quick ratio
0.68
Net debt/EBITDA
4.09
Margins
EBITDA margin
11.5%
Gross margin
73.2%
Net margin
0.6%
Operating margin
3.9%
Efficiency
Return on assets
0.3%
Return on equity
0.9%
Return on invested capital
4.4%
Return on capital employed
3.7%
Return on sales
5%
Dividend
Dividend yield
2.29%
DPS
$3
Payout ratio
2,142.9%

MRK stock price

How has the Merck stock price performed over time
Intraday
2.93%
1 week
4.38%
1 month
4.32%
1 year
12.18%
YTD
19.9%
QTD
-0.93%

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$60.12B
Gross profit
$43.99B
Operating income
$2.36B
Net income
$365M
Gross margin
73.2%
Net margin
0.6%
MRK's net margin has dropped by 98% year-on-year and by 92% since the previous quarter
The net income has dropped by 97% year-on-year and by 92% since the previous quarter
Merck's operating income has plunged by 87% YoY and by 70% from the previous quarter
Merck's operating margin has shrunk by 87% YoY and by 70% QoQ

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
MRK P/E details
P/E
933.71
P/B
8.81
P/S
5.52
EV/EBIT
118.85
EV/EBITDA
52.11
EV/Sales
5.98
The EPS has plunged by 98% YoY and by 92% from the previous quarter
The price to book (P/B) is 31% higher than the 5-year quarterly average of 6.7 and 30% higher than the last 4 quarters average of 6.8
Merck's equity has decreased by 18% YoY and by 9% from the previous quarter
MRK's P/S is 17% above its 5-year quarterly average of 4.7 and 17% above its last 4 quarters average of 4.7

Efficiency

How efficient is Merck business performance
The company's return on assets has shrunk by 98% YoY and by 93% QoQ
Merck's ROE has plunged by 97% YoY and by 92% from the previous quarter
The ROIC has shrunk by 84% YoY and by 65% QoQ
The ROS has plunged by 83% YoY and by 65% from the previous quarter

Dividends

What is MRK's dividend history
Dividend details
DPS
$3
Dividend yield
2.29%
Payout ratio
2,142.9%
Recent dividends

Financial health

How did Merck financials performed over time
The total assets is 55% more than the total liabilities
MRK's quick ratio is down by 27% year-on-year and by 18% since the previous quarter
The current ratio has contracted by 15% YoY and by 9% from the previous quarter
MRK's debt is 7% smaller than its equity
The debt to equity has grown by 39% YoY and by 9% from the previous quarter
Merck's equity has decreased by 18% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.